Following this rationale, the combination of anti-ERBB2 agents with proteasome inhibitors (which block IκB degradation and thus NF-κB activation) [31] and NF-κB inhibitors [26, 32] has been successfully tested as a novel therapeutic strategy for treating ERBB2-positive BC patients. The gene discussed is ERBB2; the disease is breast cancer.